据央视新闻报道，今天，国家首次冠脉支架（coronary stents）集中带量采购报价工作结束，10个产品拟中选，涉8家企业，包含中外企业。
经本次集采，支架价格从均价1.3万元左右下降至700元左右，预计患者将于明年1月用上降价后的中选产品。
Coronary stents, once priced at more than 10,000 yuan (US$1,500) each, are expected to become available in Chinese hospitals at roughly 1,000 yuan for the treatment of coronary heart disease.
That estimate comes from the results of the initial round of the Chinese government’s centralized procurement program for high-value medical commodities, which were unveiled Thursday in north China’s Tianjin city.
The 10 varieties of coronary stents that were successful following bidding saw their average price down to around 700 yuan from about 13,000 yuan, according to the office in charge of the program.
经过本次集采，支架价格与2019年相比，拟中选产品平均降价93%，国内产品平均降价92%，进口产品平均降价95%，按意向采购量计算，预计节约109亿元。
The average price for the same products from the same enterprises has fallen 93 percent from 2019. The average price fall for domestically made products is 92 percent, and 95 percent for imports.
It is estimated that the price cut due to centralized purchasing will save patients some 10.9 billion yuan in related expenses.
本次集中带量采购的冠脉支架材质为钴铬合金或铂铬合金，载药种类为雷帕霉素及其衍生物，采购周期为两年。
国家组织冠脉支架集中带量采购是治理高值医用耗材价格虚高、流通乱象的重要举措，是全面深化医药领域集中采购改革的关键一环。采购价格大幅降低，将显著减轻群众医药费用负担。
▌降价后，质量如何保障？
据央视新闻消息，在集中招采前，天津有关部门密集调研了医疗器械质量监督检验中心，对检测能力进行摸底，保证中选产品质量可追溯。天津市医保局副局长张铁军表示，加大监督、抽检的力度，保障在市场流动的产品全部合格。对产品的从生产、流通到使用，全周期的一个监管，保证了产品质量的可追溯性。
▌限定了支架的材质，会不会限制医生的临床选择？
不同生产企业、不同品牌的心脏支架在临床使用中70%到80%可相互替代，仅有少数不可替代的情况，主要是由于支架直径与长度有特殊规格。目前主流品牌的规格均比较齐全，均能满足80%左右的临床常见情况。
编辑：左卓
来源：央视新闻 新华网
双语君有视频号啦！
长按二维码关注我们
↓↓↓
推 荐 阅 读
